Tasigna receives FDA approval - hope to chronic myeloid leukemia
Cancer Drug Approval
Tasigna produced responses in 40% of patients with Philadelphia chromosome-positive chronic myeloid leukemia resistant or intolerant to prior cancer treatment.
Share this content.
If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.